According to an unnamed pharmaceutical announcement, the 10th meeting of the sixth board of directors of the company deliberated and passed the “Proposal on Proposed Additional Financial Assistance to the Holding Sun Company”. Due to the business development needs of Gukang Pharmaceutical Holding Company, the company plans to use idle capital to provide it with financial support of no more than 45 million yuan, with an annual interest rate of 1.3%. The loan period is within 12 months from the date of review and approval by the board of directors. The Board authorized management to sign the relevant agreement. This funding does not constitute a related transaction or major asset restructuring, and there is no need to submit it to the shareholders' meeting for consideration. The result of the vote was 11 votes in agreement, 0 against, and 0 abstentions.

According to an unnamed pharmaceutical announcement, the 10th meeting of the sixth board of directors of the company deliberated and passed the “Proposal on Proposed Additional Financial Assistance to the Holding Sun Company”. Due to the business development needs of Gukang Pharmaceutical Holding Company, the company plans to use idle capital to provide it with financial support of no more than 45 million yuan, with an annual interest rate of 1.3%. The loan period is within 12 months from the date of review and approval by the board of directors. The Board authorized management to sign the relevant agreement. This funding does not constitute a related transaction or major asset restructuring, and there is no need to submit it to the shareholders' meeting for consideration. The result of the vote was 11 votes in agreement, 0 against, and 0 abstentions.